Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MDB Capital Holdings, LLC - Class A common (NQ: MDBH )

7.640 -0.590 (-7.17%)
Streaming Delayed Price Updated: 3:20 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MDB Capital Holdings, LLC - Class A common

< Previous 1 2 Next >
MDB Capital Holdings Provides Third Quarter 2024 Update
Management to Host Conference Call Today at 4:30 p.m. ET 
From MDB Capital Holdings, LLC
Via GlobeNewswire
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development 
From Invizyne Technologies, Inc.
Via GlobeNewswire
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
From MDB Capital Holdings, LLC
Via GlobeNewswire
Invizyne Technologies Announces Closing of Initial Public Offering
From Invizyne Technologies, Inc.
Via GlobeNewswire
Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology 
From Invizyne Technologies, Inc.
Via GlobeNewswire
Invizyne Technologies Begins Trading on NASDAQ
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" 
From Invizyne Technologies, Inc.
Via GlobeNewswire
Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" 
From Invizyne Technologies, Inc.
Via GlobeNewswire
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” 
From Invizyne Technologies, Inc.
Via GlobeNewswire
MDB Capital Teams with TCA Venture Group to Bring New Insights and Public Venture Opportunities to Angel Investors
From MDB Capital Holdings, LLC
Via GlobeNewswire
MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q2 2024
MDB Capital Holdings just reported results for the second quarter of 2024. 
Via InvestorPlace
MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
From MDB Capital Holdings, LLC
Via GlobeNewswire
Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics
From PatentVest, Inc.
Via GlobeNewswire
MDB Capital Expands Board, Appoints Daniel Torpey as New Director
From MDB Capital Holdings, LLC
Via GlobeNewswire
New PatentVest Pulse Report Reveals Transformative Trends in Portable ECG Monitoring
From PatentVest, Inc.
Via GlobeNewswire
MDB Capital Holdings Unveils Unified Corporate Branding
From MDB Capital Holdings, LLC
Via GlobeNewswire
MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q1 2024
MDB Capital Holdings just reported results for the first quarter of 2024. 
Via InvestorPlace
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
From Invizyne Technologies, Inc.
Via GlobeNewswire
MDB Capital Holdings Year-End Update
Management to Host Zoom Webinar Today at 4:30 p.m. ET 
From MDB Capital Holdings, LLC
Via GlobeNewswire
MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal Year 2023 Results Webinar on Wednesday April 17, 2024 at 4:30 PM Eastern Time
From MDB Capital Holdings, LLC
Via GlobeNewswire
MDBH Stock Earnings: MDB Capital Holdings Reported Results for Q4 2023
MDB Capital Holdings just reported results for the fourth quarter of 2023. 
Via InvestorPlace
5 Tech Stocks to Buy Now, Ahead of the Q1 Reports
Tech stocks had a market reset in Q1 2024 and are now in a position to rally higher with analysts' revisions to lead the price action. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
From Invizyne Technologies, Inc.
Via GlobeNewswire
MDB Capital Holdings Issues Annual Letter to Shareholders
From MDB Capital Holdings, LLC
Via GlobeNewswire
MDB Capital Holdings Reports Third Quarter 2023 Results
From MDB Capital Holdings, LLC
Via GlobeNewswire
Michael Burns Joins Invizyne as Executive Vice President of Energy Transition
From Invizyne Technologies, Inc.
Via GlobeNewswire
MDB Capital Holdings to Host Third Quarter 2023 Results Conference Call on November 15, 2023 at 4:30 PM Eastern Time
From MDB Capital Holdings, LLC
Via GlobeNewswire
Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization 
From Invizyne Technologies, Inc.
Via GlobeNewswire
Birkenstock Drops Over 12% In Market Debut
Shares of German shoe brand Birkenstock dropped over 12% in the stock's public market debut on Wednesday. The stock opened at $41 after the company known for its Arizona sandals priced its IPO at $46... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market 
From Invizyne Technologies, Inc.
Via GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.